Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.76 |
| ▸ | CASP2 | P42575 | 1/20 | 0.71 |
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.64 |
| ▸ | FAAH | O00519 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.59 |
| ▸ | CNR2 | P34972 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 4/20 | 0.59 |
| ▸ | PPARD | Q03181 | 4/20 | 0.59 |
| ▸ | PPARA | Q07869 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31272573 | 1.00 | EPHX2 (0.76) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL2639478 | 1.00 | EPHX2 (0.76) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL34460550 | 1.00 | EPHX2 (0.76) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL6277687 | 1.00 | EPHX2 (0.76) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL18972772 | 1.00 | EPHX2 (0.76) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL1055700 | 0.98 | EPHX2 (0.73) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL23052005 | 0.96 | EPHX2 (0.81) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL2150959 | 0.96 | EPHX2 (0.81) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL8041499 | 0.96 | EPHX2 (0.81) | EPHX2CASP2NAAAKDM4EPLA2G2A | |
| SCHEMBL22684645 | 0.96 | EPHX2 (0.81) | EPHX2CASP2NAAAKDM4EPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180104185-A1 | LIQUID COMPOSITIONS CAPABLE OF FOAMING AND INCLUDING ACTIVE AGENTS, AND METHODS FOR MAKING OR DEVELOPING SAME | MIKA PHARMA GMBH | 2018-04-19 | — | — | US | disclosed |
| US-9693956-B2 | Liquid compositions capable of foaming and including active agents, and methods for making or developing same | MIKA PHARMA GMBH | 2017-07-04 | — | — | US | disclosed |
| US-20160022579-A1 | Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same | MIKA PHARMA GMBH | 2016-01-28 | — | — | US | disclosed |
| US-9005626-B2 | Liquid compositions capable of foaming and including active agents, and methods for making or developing same | MIKA PHARMA GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| WO-2014078690-A1 | DI-MACROCYCLES | LUMIPHORE, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20110269704-A1 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA PHARMA GESELLSCHAFT FUR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110059117-A1 | Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same | MIKA PHARMA GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | EPHX2 4151/4885CASP2 3398/4885NAAA 2386/4885 |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | EPHX2 4151/4885CASP2 3398/4885NAAA 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.